FDA Extends Orladeyo Pellets to Patients 12 and Up

FDA approved extending BioCryst Pharmaceuticals' oral-pellet formulation of Orladeyo (berotralstat) to patients 12 years and older on 21 October 2026, giving adolescents and adults with hereditary angioedema who struggle to swallow capsules an FDA-approved alternative dosage form. It is a line extension, not a new drug or a new indication: Orladeyo capsules have been available to this age group for years, and the pellet itself was already approved in December 2025 for children as young as two.

What actually changed

This is a dosage-form approval, not a new-molecule or new-indication approval, and the distinction matters for how RA/QA teams should read it. Berotralstat capsules have carried FDA approval for HAE prophylaxis in patients 12 and older for years. BioCryst separately developed and won approval for a 150mg oral-pellet formulation in December 2025, but that approval covered only the youngest patients — ages 2 to under 12 — who often cannot swallow a capsule at all. The October 21, 2026 action extends the already-approved pellet formulation upward, to the 12-and-older population that could already take the capsule but, for some patients, struggles to do so reliably on a chronic, once-daily regimen.

Why a pellet formulation exists at all

HAE prophylaxis is a long-term, often lifelong regimen: patients take berotralstat daily to prevent swelling attacks, not just during an acute episode. A capsule that is easy for most adults is a real adherence barrier for some — adolescents transitioning from pediatric to adult dosing, adults with dysphagia from unrelated conditions, or anyone who has historically needed to open capsules and mix the contents with food, an off-label workaround with no FDA-reviewed data behind it. An approved pellet formulation gives prescribers a labeled alternative instead.

What this means operationally

• Prescribers: the pellet formulation is now labeled for the full population already eligible for the capsule (12 and older) as well as younger children, rather than being a pediatric-only option — a formulary and prior-authorization detail payers and specialty pharmacies will need to update.
• RA/QA at BioCryst and comparator HAE drug makers: this is a reminder that dosage-form line extensions for an already-marketed rare-disease drug go through the sNDA pathway on their own timeline, separate from the parent molecule's original approval — relevant for sponsors planning similar swallowing-alternative formulations.
• Patient access teams: expect questions from patients and caregivers about switching between capsule and pellet formulations; the approved use case is swallowing difficulty, not general preference, so clinical justification will likely matter for coverage.

What is not yet settled

Public reporting on the approval, drawn from BioCryst's own announcement and trade coverage, confirms the extended age indication and the approval date but does not establish the complete updated label language — exact dosing equivalence between pellet and capsule formulations, storage and administration instructions, and any new safety language belong in FDA's official prescribing information once published. Regulatory and medical affairs teams should confirm against that primary document, not secondary coverage, before updating patient-facing materials.

Frequently asked questions

What did FDA approve, and when?

On 21 October 2026, a supplemental NDA extending the 150mg Orladeyo (berotralstat) oral-pellet formulation to HAE patients 12 and older, as an alternative to the capsule for those with swallowing difficulty.

Is this a new drug or a new indication?

No. Orladeyo capsules were already approved for this age group, and the pellet formulation was already approved for ages 2 to under 12 since December 2025. This extends the pellet formulation's approved age range, not the drug's indication.

Why would an adult or adolescent need a pellet instead of a capsule?

Some patients 12 and older have difficulty swallowing capsules reliably on a chronic regimen; the pellet gives prescribers an FDA-approved alternative rather than relying on off-label capsule manipulation.

What is berotralstat's mechanism?

An oral, once-daily plasma kallikrein inhibitor taken for routine prophylaxis to prevent hereditary angioedema attacks.